The prognosis of advanced melanoma remains poor in spite of treatment advances, emphasizing the importance of additional preventive measures. Flavonoids, natural components of our diet, are being investigated for their chemopreventive/therapeutic properties. Microphthalmia-associated transcription factor (Mitf), downstream of the Wnt/b-catenin pathway, has become an important prognostic marker of melanoma. In this study, we show that treatment of 451Lu melanoma cells with the dietary flavonoid fisetin (3,7,3 0 , 4 0 -tetrahydroxyflavone) resulted in decreased cell viability with G1-phase arrest and disruption of Wnt/b-catenin signaling. This was accompanied by a decrease in the expression of Wnt protein and its co-receptors, as well as by a parallel increase in the expression of endogenous Wnt inhibitors. Fisetin-treated cells showed increased cytosolic levels of Axin and b-TrCP and decreased phosphorylation of glycogen synthase kinase 3b associated with decreased b-catenin stabilization. Fisetin-mediated interference with the functional cooperation between b-catenin and T-cell factor (TCF)-2 resulted in the downregulation of positively regulated TCF targets, such as c-myc, Brn-2, and Mitf. Flow-cytometric analysis of Mitf-overexpressing cells showed that fisetin repressed Mitf-induced cell proliferation. Finally, administration of fisetin to 451Lu-xenografted nude mice resulted in the inhibition of tumor development and decreased Mitf expression. Our data suggest that fisetin can be developed as an effective agent against melanoma because of its potential inhibitory effect on b-catenin/Mitf signaling.
INTRODUCTION
Constitutive activation of the Wnt signaling pathway is a feature of a number of cancers including malignant melanoma with aberrant nuclear accumulation and subsequent upregulation of b-catenin transcription response (Larue and Delmas, 2006) . Binding of Wnt to the transmembrane Frizzled receptor prompts Dishevelled to prevent proteolytic destruction of b-catenin. Stabilized b-catenin then transits to the nucleus, where it converts transcriptional repressors known as T-cell factors (TCFs) into activators and regulates cell fate through gene expression (Bowerman, 2008) . Microphthalmia-associated transcription factor (Mitf) has been shown to reside downstream of the canonical Wnt pathway during melanocyte differentiation from pluripotent neural crest cells. Although the expression of many melanocytic/ pigmentation markers is lost in human melanoma, Mitf expression remains intact, even in non-pigmented tumors, suggesting a role for Mitf beyond its role in differentiation (Widlund et al., 2002) . It has been suggested that Mitf can redirect b-catenin transcriptional activity away from canonical Wnt signaling-regulated genes toward Mitf-specific target promoters, thereby enhancing the repertoire of genes regulated by b-catenin (Schepsky et al., 2006) .
Epidemiological evidence suggests that a plant-based diet rich in flavonoids is effective against cancer (Kundu and Surh, 2005; Khan et al., 2008) . Thus, flavonoids have become not only important potential chemopreventive agents but also therapeutic natural agents. Fisetin (3,7,3 0 ,4 0 -tetrahydroxyflavone) belongs to the flavonol subgroup of flavonoids together with quercetin, myricetin, and kaempferol, and is found in many fruits and vegetables, such as strawberries, apples, persimmons, kiwi, onions, and cucumbers. Fisetin has been shown to facilitate long-term memory potentiation and to enhance object recognition in mice, and reduced behavioral deficits following stroke in other animal models (Maher et al., 2007) . Emerging data from our laboratory and from that of others suggest that fisetin in addition to its neuroprotective effects possesses anti-cancer properties . The aim of this study was to investigate whether fisetin can inhibit the growth of highly aggressive human melanoma cells and to define the molecular basis of this effect. In this study, we determined that fisetin exerts its anti-proliferative actions in human melanoma cells by interference with the key elements of the Wnt pathway. In addition, we investigated the effect of fisetin on cellular localization of b-catenin and studied the impact of fisetin on TCF-2/LEF-1-regulated proteins with emphasis on Mitf as a direct target of Wnt/b-catenin signaling.
RESULTS

Fisetin decreases the viability of 451Lu human melanoma cells
We evaluated the effect of fisetin on the growth of metastatic 451Lu human melanoma cells, which exhibit constitutive Wnt signaling in addition to harboring a mutation in the B-Raf gene (Maddodi et al., 2010; Tarapore et al., 2010) . Fisetin treatment of 451Lu cells at various time points displayed a dose-dependent decrease in cell viability as analyzed by the MTT (3-(4,5 dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay ( Figure 1a ). IC 50 was estimated to be 80, 37.2, and 17.5 mM at 24, 48, and 72 hours, respectively. These observations led to the selection of doses for further mechanistic studies that ranged from 40 to 80 mM over 24 hours. The dose-dependent effect of fisetin on cellular morphology after 24 hours treatment as observed by phasecontrast microscopy can be visualized in Figure 1b . Relative to 451Lu cells, normal human melanocytes were resistant to fisetin-mediated growth repression (data not shown).
Fisetin induces G1-phase arrest in 451Lu human melanoma cells
To examine the effect of fisetin on 451Lu cell cycle, flowcytometric analysis was performed, and the expression of cell cycle-regulatory molecules was evaluated by western blot analysis. Figure 1c shows that fisetin treatment arrested cells in the G1 phase, with an increase in the mean percentage (68.2 and 74.5% at 60 and 80 mM, respectively) of cells in G1 as compared with 56.6% of cells in untreated control samples. Furthermore, inhibition of cell-cycle progression by fisetin correlated with a reduction in the protein levels of cyclin-dependent kinases (cdks) -2, -4, and -6, key cell cycleregulatory proteins involved in the G1-phase progression (Figure 1d ). 
Downregulation of the Wnt protein and its co-receptors by fisetin
To assess the functional relevance of Wnt/b-catenin signaling in the context of cell-growth inhibition, we analyzed the effect of fisetin on the Wnt protein and its co-receptors. Figure 2a demonstrates that cells treated with increasing doses of fisetin showed a dose-dependent decrease in the expression of Wnt growth factor protein, Wnt5a. Interestingly, downregulation of co-receptor (Frizzled/LRP6) expressions along with a decrease in Dishevelled expression coincided with an increase in endogenous Wnt inhibitors (DKK1 and WIF) in fisetin-treated cells (Figure 2a and b). Immunofluorescence studies further elucidated this effect. b-Catenin staining was notably reduced in the nuclei of fisetin-treated melanoma cells, indicating that a significant amount of b-catenin was phosphorylated and degraded resulting in decreased nuclear accumulation (Figure 2c , bottom). We investigated whether the inhibitory effect of fisetin on b-catenin expression extended to other melanoma cell lines. For this, we selected two cell lines, WM35 and Mel928, with increased b-catenin levels and performed MTT assay and western blot analysis after exposing them to increasing doses of fisetin. As shown in Figure 2d , fisetin treatment effectively decreased b-catenin protein expression in both cell lines accompanied by a dose-dependent inhibition in growth and viability. two distinct mechanisms: augmenting the destruction complex and increasing proteasomal degradation. Figure 3a shows an increase in the expression levels of Axin and b-TrCP proteins in the cytosol of fisetin-treated cells, indicating a stimulatory effect of fisetin on destruction complex proteins. To substantiate the involvement of Axin in fisetin-mediated decrease in b-catenin levels, we used an in vitro pull-down assay to assess the binding of Axin with endogenous b-catenin in the lysates of fisetin-treated cells (Figure 3b ). 451Lu cells were treated with fisetin for 24 hours, and cell lysates were incubated with agarose beads coated with b-catenin antibody and subjected to western blotting. As shown in Figure 3b , treatment of 451Lu cells with fisetin significantly increased the amount of Axin associated with the pull down. The phosphorylation of b-catenin by glycogen synthase kinase 3b (GSK3b) targets it for proteasomal degradation. GSK3b activity, in turn, is regulated by its phosphorylation status, with phosphorylation at Ser 9 rendering the protein functionally inactive. Figure 3a shows that fisetin treatment resulted in decreased phosphorylation of GSK3b in a dosedependent manner. To establish whether fisetin-induced suppression of b-catenin is mediated through a GSK3bdependent mechanism, we assessed the effect of fisetin on b-catenin expression in combination with the known GSK3b inhibitor, LiCl. Immunoblot analysis showed that LiCl could protect 451Lu cells from fisetin-mediated suppression of b-catenin expression (Figure 3c , top). As several structurally diverse inhibitors of GSK3 must affect the given biological process similarly before concluding that fisetin is acting through inhibition of GSK3, we co-treated 451Lu cells with fisetin and the highly selective GSK3b inhibitor, BIO, and analyzed lysates for b-catenin protein levels. As before, fisetin was unable to counteract BIO-facilitated activation of b-catenin, indicating that GSK3b had a key role in fisetininduced b-catenin degradation (Figure 3c , middle).
b-TrCP is involved in fisetin-mediated b-catenin proteolysis b-TrCP, the F-box protein in the E3 ubiquitin ligase complex, binds and tags b-catenin for proteasomal degradation (Liu et al., 2004) . Fisetin treatment increased the expression of b-TrCP in a dose-dependent manner parallel to that of b-catenin repression, indicating a mechanistic link between two diverse responses (Figure 3a ). To further examine this, we used MG-132 to block proteasome-mediated protein degradation. Treatment with fisetin consistently induced a decrease in b-catenin levels in 451Lu melanoma cells. However, the effect of fisetin on the reduction of b-catenin was abrogated by the addition of MG-132, indicating that fisetin induces the degradation of b-catenin in a proteasomedependent manner (Figure 3c , bottom). Time-dependent studies further verified the role of b-TrCP in the suppression of b-catenin expression by fisetin ( Figure 3d ). Next, we investigated whether fisetin promoted b-catenin degradation by regulating b-TrCP gene expression or by increasing the stability of the protein. Reverse transcription-PCR analysis indicated that exposure of 451Lu cells to different doses of fisetin did not affect the mRNA level of b-TrCP (data not shown), despite a robust increase in its protein level (Figure 3a and d) . This finding suggested that the upregulation of b-TrCP by fisetin was mediated by prolonging its protein stability. To verify this, we assessed the effect of fisetin on the half-life of b-TrCP in 451Lu cells co-treated with fisetin and the protein synthesis inhibitor, cycloheximide. In untreated cells, b-TrCP had a half-life of B6 hours, whereas in fisetin-treated cells, the protein level of b-TrCP remained unaltered throughout the course of cycloheximide treatment (Figure 3d ).
Pleiotropic effects of fisetin on multiple b-catenin signaling targets
We next examined the effect of fisetin on the cadherin signaling network. As shown in Figure 4a , fisetin caused differential repression of the cadherin family of proteins with a decrease in N-cadherin and an increase in b-catenin's binding partner, E-cadherin. The upregulation of cadherinassociated p120 catenin protein expression in fisetin-treated cells reported to be significantly reduced in cancer tissues was also noteworthy (Perez- Moreno and Fuchs, 2006) .
Fisetin interferes with the functional cooperation between TCF-2 and b-catenin
As b-catenin transactivates gene expression in a complex with TCF proteins, we studied the effect of fisetin on the TCF complex using mobility shift assay. Figure 4b (top) shows a dose-dependent decrease of the TCF complex in fisetintreated 451Lu cells. We next examined the effect of fisetin on different proteins of the TCF family. Fisetin caused a differential repression of these proteins in the order of TCF-24TCF-1 with minimal change in TCF-4 (Figure 4b , bottom). We wanted to know whether fisetin-regulated b-catenin-dependent control is mediated through its effect on TCF-2-b-catenin interaction. Treatment of cells with TCF-2-small-interfering RNA, but not with scrambled RNA, resulted in a significant decrease in the protein expression of b-catenin (Figure 4c, top) . This decrease in b-catenin expression was comparable with that observed in fisetintreated cells and was more pronounced when cells were co-treated with TCF-2-small-interfering RNA and fisetin. A pull-down assay with b-catenin further identified TCF-2 as the key regulator of b-catenin-mediated effects in fisetintreated cells (Figure 4c , bottom). We next studied the effect of fisetin on the protein expression of known TCF-regulated genes. Figure 4d shows that fisetin treatment resulted in downregulated protein levels of positively regulated b-catenin/TCF targets, such as c-myc, Brn2, and Mitf.
Suppression of proliferation by fisetin involves Mitf
We then examined the effect of fisetin on Mitf, critical in melanoma cell proliferation. Reduced levels of Mitf protein and mRNA in fisetin-treated cells suggested that fisetininduced Mitf repression was mediated at the transcriptional level ( Figure 5a ). Furthermore, downregulated Mitf expression was accompanied by a decrease in the anti-apoptotic Bcl-2 protein expression (data not shown). To examine the involvement of Mitf in b-catenin's mitogenic effect, we overexpressed Mitf in 451Lu melanoma cells. Flow-cytometric analysis revealed that the ectopic expression of Mitf resulted in an increase in the S-phase fraction of the cell cycle as compared with untreated control cells (39.5 vs. 34.5%), whereas fisetin-treated cells showed a significant decrease in S-phase content (10 vs. 34.5%), respectively. Moreover, fisetin relieved cells from Mitf-induced cell proliferation (18 vs. 39.5%) (Figure 5b and c) .
Fisetin inhibits the growth of 451Lu human melanoma cells and decreases Mitf levels in athymic mice
Although our in vitro data unambiguously demonstrated that fisetin had potent growth-inhibitory activity, questions remained regarding its in vivo efficacy. Athymic nude mice were implanted with 451Lu melanoma cells and divided into three cohorts, each with six animals that were administered fisetin/vehicle intraperitoneally. The first group received the vehicle (DMSO) only, whereas the second and the third groups received fisetin 1 and 2 mg per animal (45 and 90 mg kg À1 body weight), respectively. Fisetin was administered twice weekly and seemed tolerable as depicted by body weight measurements (Figure 6a ). On day 7, the appearance of small tumors was observed in the control cohorts, followed by tumors in the fisetin-treated groups by day 14. A smaller average tumor volume was consistently observed in mice treated with fisetin. This was more marked in animals (Figure 6b and c) .
In the control group, the average tumor volume of 788.5 mm 3 was reached at day 45, whereas mice receiving 1 mg fisetin had an average tumor volume of 263.8 mm 3 representing a significant suppression in tumor growth by 66.6% (P ¼ 0.0012). The 2 mg group, at the same time point had an average tumor volume of 331 mm 3 and tumor suppression by B58.1% (P ¼ 0.0007). A significant decrease in the protein expression of Mitf, as well as downstream target Bcl-2 and cdk-2 was observed in treated mice, indicating that the growth-inhibitory effect of fisetin extended to the in vivo situation (Figure 6d and e ).
DISCUSSION
Malignant melanoma is a deadly human cancer with no effective cure for metastatic disease. The aim of this study was to identify natural compounds that may be used against melanoma for chemopreventive/therapeutic purposes. Not only does their use circumvent the need to introduce foreign compounds into the human body but also natural agents are expected, in general, to be less toxic, more accessible, and less expensive than synthetic agents . Strategies are being developed to limit constitutive Wnt signaling involved in the genesis of a number of malignancies, including melanoma (Takahashi-Yanaga and Sasaguri, 2007) . Fisetin-mediated decrease in the expression of transmembrane receptors, Frizzled and LRP6, as well as upregulation of the Axin protein indicates that fisetin interferes with the interaction of LRP6, Axin, and b-catenin (Figures 2 and 3) . In addition, an increase in the endogenous Wnt inhibitors DKK and WIF1 may also contribute to suppress the canonical Wnt pathway in fisetin-treated cells. Activated Wnt signaling positively feeds into the phosphoinositide 3-kinase/Akt pathway through inhibition of GSK3, a key component shared by both pathways (Fang et al., 2007) . Fisetin treatment resulted in dephosphorylating activation of GSK3b (Figure 2) . Moreover, fisetin suppressed Akt activation in 451Lu melanoma cells through decreased phosphorylation at both Ser 473 and Thr 308 residues (data not shown). This is important as Akt is believed to act as a molecular switch that increases angiogenesis and generation of superoxide, fostering more aggressive behavior in melanoma tumors (Govindarajan et al., 2007) .
Decreased HOS/b-TrCP-2 levels hinder the degradation of b-catenin (Spiegelman et al., 2002) . Fisetin and other dietary flavonoids have been shown to enhance proteasome activity and to promote nerve cell survival (Maher, 2008) . This is consistent with our data that indicate that fisetin increased b-TrCP expression levels through protein stabilization, thereby facilitating ubiquitin-dependent proteasomal degradation of b-catenin (Figure 3) . The ability of fisetin to target b-TRCP further provides a molecular basis to account for its reported effect on modulating the expression of cell cycle-regulatory proteins (Lu et al., 2005) .
The transcriptional activity of b-catenin through its interaction with the TCF family is recognized as the major effector of the Wnt signaling pathway, and its activation has been associated with malignancy (Larue and Delmas, 2006) . Our data show that fisetin interferes with the b-catenin/TCF axis through targeting the TCF-2/LEF-1 protein in 451Lu melanoma cells (Figure 4 ). This effect of fisetin was specific for melanoma cells when compared with other cancer cell lines in which fisetin exerts its effect through targeting TCF-4 . Analysis of protein expression of fisetin-treated melanoma cells showed a dose-dependent reduction in the levels of TCF targets involved in the b-catenin signaling network, including ubiquitous genes such as c-myc, cell lineage-restricted genes such as Brn2, and melanocyte-specific genes such as Mitf (Figures 4 and 5) . The retention of Mitf expression in the vast majority of human melanomas has led to its use as a diagnostic tool in this malignancy. Suppression of melanoma clonogenic growth by disruption of b-catenin-TCF-2 could be rescued by constitutive Mitf (Widlund et al., 2002) . In addition, reduction of Mitf activity sensitizes melanoma cells to chemotherapeutic agents. It is suggested that targeting Mitf in combination with B-RAF or cdk inhibitors may offer a rational therapeutic avenue into melanoma, a highly chemotherapy-resistant neoplasm (Garraway et al., 2005) . Our data showed that fisetin, a known cdk inhibitor, was able to override the proliferative effect of Mitf and thus induce growth repression in human melanoma cells. The inhibitory effect of fisetin was evident in tumor-xenografted mice as well. Treatment with fisetin at two different doses significantly slowed the progression of 451Lu tumor growth in nude mice as shown in Figure 6 . This inhibition of tumor growth was coupled with a decrease in Mitf levels. Thus, it is conceivable that fisetin can inhibit melanoma cell proliferation by targeting the Wnt/ b-catenin pathway and its downstream targets in conjunction with its direct effect on the cdk-cyclin network. It will be of interest to determine whether other Mitf-regulated genes can be targeted by fisetin to modulate the mitogenic response. Using dose scaling as advised in the Food and Drug Administration guidelines, the human equivalent dose of fisetin in our in vivo study translated to B97 mg of fisetin in a 60-kg adult and represents a reasonable starting point for future clinical investigations.
In summary, our goal in this study was to gain a mechanistic understanding of the mode of action of fisetin in melanoma cells. Our in vitro studies showed that a decrease in b-catenin levels, induction of b-TrCP, and a reduction of Mitf mRNA and protein levels are possible criteria for fisetin-mediated suppression of Wnt signaling in melanoma cells ( Figure 6 ). Importantly, this was reflected in our in vivo studies that showed significant growth inhibition in mice implanted with melanoma xenografts and decreased Mitf levels upon treatment with fisetin with two different doses. In contemplating future applications, there is strong evidence that this compound may be a strong candidate in cancer prevention and therapeutic strategies.
MATERIALS AND METHODS
Materials
Fisetin, LiCl, C2211 (MG-132), and cycloheximide were purchased from Sigma Chemical (St Louis, MO). BIO was obtained from Calbiochem (Gibbstown, NJ).
Antibodies
Antibodies were obtained from Cell Signaling Technology (Beverly, MA). Frizzled, WIF1, b-TrCP, and Mitf antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). www.jidonline.org 1297 DN Syed et al.
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Cell culture/treatment
Mel 928 (ATCC, Manassas, VA), WM35, and 451Lu human melanoma cell lines kindly provided by Dr Meenhard Herlyn (Wistar Institute, Philadelphia, PA) were cultured in MEM obtained from Gibco (Carlsbad, CA), with 10% fetal bovine serum and 1% penicillin-streptomycin, at 37 1C with 5% CO 2 in a humid environment. For dose/time-dependent studies, cells (70% confluent) were treated with fisetin dissolved in DMSO (20-80 mM) for 24 hours at 37 1C in media and harvested for further studies. For time-dependent studies, cells treated with 60 mM fisetin were harvested at the specified time points.
Cell viability
Cell viability was determined by MTT assay as described previously (Johnson et al., 2008) .
Cell-cycle analysis and apoptosis
451Lu cells treated with/without fisetin for 24 hours were processed for labeling with fluorescein-tagged dUTP nucleotide and propidium iodide using the Apo-Direct kit (Phoenix Flow Systems, San Diego, CA) and analyzed using ModiFitLT V3.0. (Verily Software House, Topsham, ME) software.
Preparation of cell lysates
After fisetin treatment, whole, cytosolic, and nuclear lysates were prepared, and western blot analysis performed as described previously (Syed et al., 2007) .
Immunochemistry
Immunocytochemical analysis of 451Lu cells, seeded in tissue culture slides treated with/without fisetin was performed as described earlier (Syed et al., 2007) . Tumor tissues collected from mice fixed in 10% formalin were blocked (5% goat serum/ phosphate-buffered saline) for 30 minutes after deparaffinization and rehydration in xylene and graded series of ethanol. After incubation with Mitf-and horseradish peroxidase-conjugated secondary antibodies, slides were counterstained with hematoxylin and immunoreactive complexes detected using 3,3 0 -diaminobenzidene (Dako, Carpinteria, CA). Sections were visualized on a Zeiss-Axiophot DMHT microscope (Jena, Germany) and images captured using a camera attached to computer. Figures were composed using Adobe Photoshop 7.0 (Adobe Systems, Mountain View, CA).
Transient transfection and RNA interference
Transfection of cells was performed by electroporation using an Amaxa Nucleofector according to the manufacturer's protocol (Amaxa Biosystems, Lonza , Allendale, NJ) with the pCMV5a-Mitf plasmid and a corresponding vector control pCMV5a plasmid/small-interfering RNA against TCF-2 with scrambled small-interfering RNA as control (Santa Cruz Biotechnology). Transfected cells were harvested 24 hours after fisetin treatment for immunoblot/flow-cytometric analysis.
Electrophoretic mobility shift assay
Electrophoretic mobility shift assay for TCF was performed using lightshift chemiluminiscent electrophoretic mobility shift assay kit (Pierce, Rockford, IL) as per the manufacturer's protocol. In brief, double-stranded TCF oligonucleotide 5 0 -AGTTGAGGGG ACTTTCCCAGGC-3 0 ; 3 0 -TCAACTCCCCTGAAAGGGTCCG-5 0 was labeled using the Biotin 3 0 -end labeling kit as described previously (Syed et al., 2007) .
Xenograft studies
Athymic (nu/nu) female nude mice (NxGen Biosciences, San Diego, CA) were housed under pathogen-free conditions, in the University of Wisconsin Animal Resource Facility, with a 12-hour light/12-hour dark schedule and fed an autoclaved diet ad libitum. Overall, 1 Â 10 6 451Lu cells suspended in Matrigel were injected subcutaneously into each flank of 18 mice randomly divided into 3 groups. The first and the second groups received an intraperitoneal injection of fisetin (1 and 2 mg per animal, respectively) dissolved in DMSO, biweekly, whereas the third group (DMSO only) served as the control group. Mice weight and tumor volumes were recorded. After 45 days, mice were killed and tumor tissues harvested. All animal experiments were approved by and carried out according to IACUC guidelines.
Statistical analysis
Results were analyzed using a two-tailed Student's paired t-test, using GraphPad QuickCalcs software (GraphPad Software, La Jolla, CA); Po0.05 was considered statistically significant.
